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This study aimed to compare the duration of protection against exercise-induced bronchoconstriction (EIB) after
inhalation of formoterol (Oxis1) Turbuhaler1 with that of terbutaline Turbuhaler1 and placebo Turbuhaler1 in
asthmatic patients treated regularly with formoterol Turbuhaler1 9mg b.i.d. and inhaled steroids.
The study, performed at three centres (Go¨teborg and Lund, Sweden, and Trondheim, Norway), consisted of an
open-label part with formoterol Turbuhaler1 9mg b.i.d. and a randomized, double-blind, cross-over part with a
single dose (on top of the regular treatment) of either formoterol Turbuhaler1 9mg, terbutaline Turbuhaler1
0?5mg or placebo Turbuhaler1. The patients attended the clinic six times: twice for screening visits, three times for
randomized treatment and once for a follow-up visit. Patients received regular b.i.d. treatment with formoterol 9 mg
for a mean period of 16 days.
Formoterol gave a post-exercise fall of 12, 10, 15 and 17% in forced expiratory volume in 1 sec (FEV1) 15min, 4,
8 and 12 h after inhalation. The differences compared with placebo (falls of 26, 22, 23 and 22%) and terbutaline
(falls of 17, 18, 22 and 22%) were all statistically significant (P50?05 for all comparisons).
Patients on regular treatment with formoterol Turbuhaler1 9 mg b.i.d. have a significant protection against EIB
up to 12 h after inhalation of formoterol 9mg. The protection was also significantly better than that of terbutaline
Turbuhaler1 0?5mg.
Key words: formoterol turbuhaler1; asthma; exercise; cold air.
RESPIR. MED. (2001) 95, 484–490 # 2001 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2001) 95, 484–490
doi:10.1053/rmed.2001.1074, available online at http://www.idealibrary.com onIntroduction
The airway response to exercise is a feature of bronchial
responsiveness. Although the mechanism is not fully
understood, it involves bronchial smooth muscle cells,
mast cells and neurones (1), with the release of media-
tors (2). Respiratory heat loss, resulting in water loss, is
one of the hypotheses for the cause of exercise-induced
bronchoconstriction (EIB) (3). Cold air inhalation
during exercise has been shown to enhance the magnitude
of EIB (4).
Inhaled b2-adrenoreceptor agonists are the most effective
drugs for preventing EIB in patients with asthma (5,6).
However, the usefulness of most currently availableReceived 27 September 2000 and accepted in revised form 6 March
2001.
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0954-6111/01/060484+07 $35?00/0b2-agonists is limited by a rather short duration of
protection (7,8). Formoterol fumarate dihydrate (hereafter
‘formoterol’) is a long-acting b2-agonist with a rapid onset
of action and maintained bronchodilatory effect for at least
12 h (9,10). Single doses of formoterol and the other long-
acting b2-agonist salmeterol have been shown to give
significant protection up to 12 h against bronchoconstric-
tion induced by exercise and methacholine challenge.
However, it has been reported that regular use of these
drugs is associated with tolerance development resulting in
a reduced bronchoprotection (11,12).
The present placebo-controlled study was performed to
investigate whether patients on regular treatment with
for-moterol Turbuhaler1 9mg b.i.d. and using inhaled
corticosteroids would have protection against repeated EIB
for 12h after inhalation of formoterol (Oxis1) Turbuhaler1
9mg compared with terbutaline Turbuhaler1 0?5mg. To
avoid a carry-over effect, the evening dose of formoterol,
scheduled to be taken 12h prior to exercise challenge test, was
omitted.# 2001 HARCOURT PUBLISHERS LTD
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STUDY DESIGN AND PATIENTS
The study, performed at three centres (Go¨teborg and Lund,
Sweden, and Trondheim, Norway), included adult asth-
matics, diagnosed at least 6 months prior to inclusion, who
had been on regular treatment with a constant dose of
inhaled glucocorticosteroids (GCSs) for at least 30 days
before the start of the study. Lung function measured as
forced expiratory flow in 1 sec (FEV1) had to be 470% of
predicted normal value and the patient had to document a
fall in FEV1 of at least 15% after the exercise challenge test
(ECT). To exclude a late-phase reaction to exercise, peak
expiratory flow (PEF) was measured at the clinic before
ECT and at home 4, 8 and 12 h after ECT at visit 1.
The study consisted of six visits to the clinic: two screening
visits, three visits for drug tests and a follow-up visit (Fig. 1).
At visit 1, a screening ECT was performed. Patients who
demonstrated a fall in FEV1 of at least 15% after the ECT
received 9mg formoterol Turbuhaler1 (corresponding to
12mg metered dose) to be used twice daily throughout the
study, except in the evening before visits 2–5. A second
screening visit (visit 2) took place after a minimum of 4 days
and another ECT was performed. Only patients who once
again showed a fall of at least 15% in FEV1 after exercise
were allowed to continue the study and proceeded with the
open-label treatment with formoterol.
Visits 3–5 were scheduled for the morning, and a single
dose of formoterol 9 mg or terbutaline 0?5mg or placebo, on
top of the regular b.i.d. formoterol treatment, was
administered via Turbuhaler1 in a double-blind, cross-
over and randomized fashion. Fifteen minutes after drug
administration, ECT was performed. The ECT was
repeated 4, 8 and 12 h after drug administration. Visit 6
was a follow-up visit.
Between visits 1 and 5, patients were asked to fill in
diaries at home. The time of inhalation of study medication
and any use of relief medication during the night before
visits 2–5 were recorded.
ECT
EIB was determined using a standardized ECT. Patients
ran continuously for 4–8min on a treadmill with anFIG. 1. Flow chart of study design. *The evening dose of regul
{Each patient received a single dose of formoterol Turbuhaler1
Turbuhaler1 in a cross-over, randomized fashion.inclination of about 10% and at a speed that was adjusted
step-wise to produce a final pulse 80% of the predicted
maximum value. During the ECT, the patients wore a nose-
clip and breathed cold dry air (7188C) generated by a
Turboaire1 challenger (Equilibrated Bio Systems, U.S.A.)
through a mouth-piece. For each patient the individual
workload determined at visit 1 was maintained throughout
the study.
SPIROMETRY
FEV1 measurements were performed using a standard
spirometer (Vitalograph1 Alpha; Vitalograph Ltd, U.K.)
in accordance with American Thoracic Society (ATS)
acceptability and reproducibility guidelines (13).
For establishment of baseline, two FEV1 determinations
(15min apart) were performed before study drug adminis-
tration. The mean of the two FEV1 values had to be470%
of predicted normal value at visits 1–5. Moreover, baseline
FEV1 at visits 3–5 had to be within +12% of the baseline
FEV1 measured at visit 2.
Pulmonary function was evaluated by the best of two
FEV1 measurements, immediately before and after exercise,
and 5, 10 and 20min after exercise. If FEV1 was lower after
20min than after 10min, further measurements were made
every 10min until the maximum fall was observed.
STATISTICAL ANALYSIS
The bronchial response to exercise was expressed as the
maximum fall in FEV1 from the pre-exercise value:
Maximum percentage fall
 pre-exercise FEV1 ÿ lowest post-exercise FEV1
pre-exercise FEV1
 100
The maximum percentage fall was compared between
treatments with an additive analysis of variance (ANOVA)
model with factors patient, period and treatment. Ninety-
five per cent confidence intervals (CI) were constructed for
the pair-wise treatment contrasts. The values from each
ECT within a single study day were treated in separate
analyses. Formoterol was first compared with placebo and
if a statistically significant difference was found, formoterol
was then compared with terbutaline. The duration of thear formoterol Turbuhaler1 before this visit was omitted.
9 mg, terbutaline Turbuhaler1 0?5mg or placebo
486 J. VILSVIK ET AL.protective effect was evaluated by comparing active
treatment with placebo, first at 15min and then at
increasing time points for as long as the difference was
statistically significant.
The bronchodilator effect was compared between treat-
ments with a multiplicative ANOVA model with factors
patient, period and treatment and using FEV1 as covariate.
The bronchodilator effect was expressed as the FEV1 value
before ECT and as the 12-h average FEV1 (AUC/12) based
on the before ECT values.
SAFETY
As safety parameters, serum potassium, pulse and blood
pressure were measured. Also, the patients were asked
about adverse events (AEs) at all visits and routine physical
examinations were performed at visits 1 and 6.
ETHICS
The independent ethics committees of all participating
centres approved the study, and a signed consent to
participate in the study was obtained from each patient
prior to admission. The study followed the guidelines in the
Declaration of Helsinki.
Results
PATIENT DEMOGRAPHICS
In all, 52 patients with asthma (ATS definition) were
enrolled in the study. Thirty-two were given the open-label
treatment with formoterol for a mean time of 16 days
(range 8–44 days) and 26 were randomized to the double-
blind treatment. Twenty-six patients were withdrawn prior
to randomization because of a fall in FEV1515% (22
patients), a baseline FEV1570% (two patients), a late-
phase reaction (one patient) and other reasons (one
patient).TABLE 1. Patient characteristics
Patients completing
the study
26
Sex 11 men, 15 women
Mean age (range) 33 years (19–53 years)
Mean weight (range) 75 kg (53–104 kg)
Mean baseline FEV1
Visit 1 (range)
3?18 l (2?35–4?41 l)
88?7% (70?8–108?9%)
of predicted normal value
Mean baseline FEV1
Visit 2 (range)
3?21 l (2?32–4?49 l)
89?6% (70?2–110?0%)
of predicted normal value
Mean maximum fall
(range), visit 1
28?3% (15?5–51?3%)
Mean maximum fall
(range), visit 2
27?6% (16?0–48?4%)Of the 26 randomized patients, 22 had a diagnosis of
extrinsic asthma, three patients of intrinsic asthma and one
patient unspecified asthma. All 26 patients had been on
regular treatment with inhaled GCSs for at least 1 month
prior to visit 1; 12 patients used low-dose equivalent to
400mg budesonide day71, 12 used medium-dose equivalent
to 800 mg budesonide day71 and two used high-dose
equivalent to 1600 mg budesonide day71. One patient used
disodium cromoglycate on an ‘as-needed’ basis until 8 days
before visit 1. Three patients were on anti-histamines and
two patients used nasal GCSs. Nine patients used a long-
acting b2-agonist (salmeterol) until 3–8 days before visit 1.
Table 1 shows patient characteristics. All 26 randomized
patients were considered eligible for evaluation of ecacy
data and are included in the analysis.
BRONCHODILATORY EFFECT
The mean baseline FEV1 values (visits 3, 4 and 5) obtained
prior to drug inhalation were similar for all treatments:
3?10 l for terbutaline and 3?11 l for formoterol and placebo.
Formoterol increased FEV1 15min after inhalation, just
before the ECT, significantly more than placebo and
terbutaline. Terbutaline was also significantly better than
placebo (see Fig. 2). The 12-h average bronchodilatory
effect, based on the area under the curve of time vs. effect,
gave the same picture as that seen 15min after inhalation.
Results of the analyses are given in Table 2.
BRONCHOPROTECTIVE EFFECT
Formoterol gave a significantly higher degree of protection
against EIB than placebo and terbutaline at 15 min, 4, 8
and 12 h after drug administration (Fig. 3).
The degree of protection declined with time. The placebo
fall was slightly smaller during the randomized study day
(21?7–26%) than during visits 1 (28?3%) and 2 (27?6%).
The results of the statistical analyses are given in Table 3.FIG. 2. Mean FEV1 at different time points after
administration of study drug. Formoterol 9 mg (&),
terbutaline 0.5mg (*), placebo (~).
TABLE 2. Single dose effects on FEV1 (l)
Number of
patients
Baseline FEV1 (l) (unad-
justed raw arithmetic
means)
Mean FEV1 (l)
(15min after drug inhalation)
Average FEV1 (l) (during 12 h after drug
inhalation)
Contrast{ Mean (range) Est.* 95% CI P-value Est.* 95% CI P-value
Terbutaline 0?5mg 26 3?15 (2?25–4?17) 3?25 3?20 3?30 — 3?11 3?05 3?18 —
Formoterol 9 mg 26 3?17 (2?09–4?26) 3?33 3?28 3?38 — 3?26 3?19 3?32 —
Placebo 26 3?17 (2?08–4?26) 3?07 3?02 3?12 — 2?99 2?93 3?05 —
Formoterol/placebo — — 108?5 106?2 111?0 50?001 109?1 106?1 112?2 50?001
Terbutaline/placebo — — 105?9 103?6 108?2 50?001 104?3 101?4 107?2 0?004
Formoterol/terbutaline — — 102?5 100?3 104?8 0?03 104?6 101?6 107?6 0?002
CI: Confidence interval.
*Geometric means adjusted for period effects and baseline differences; {treatment ratios in %.
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There was no clinically relevant difference between treat-
ments regarding serum potassium levels, blood pressure,
pulse or AEs throughout the study.TABLE 3. Maximum fall (%) in FEV1 at different time points a
Contrast M
ECT 15min after drug inhalatio
Estimation 95% CI
Terbutaline 0?5mg 16?6 13?7 19?4
Formoterol 9mg 12?1 9?25 15?0
Placebo 26?2 23?3 29?2
Placebo-formoterol 14?1 10?0 18?2
Placebo-terbutaline 9?65 5?55 13?7
Terbutaline-formoterol 4?47 0?43 8?50
M
ECT 8h after drug inhalation
Estimation 95% CI
Terbutaline 0?5mg 22?2 19?6 24?8
Formoterol 9mg 15?0 12?4 17?6
Placebo 22?5 19?8 25?1
Placebo-formoterol 7?44 3?71 11?2
Placebo-terbutaline 0?23 73?50 3?97
Terbutaline-formoterol 7?20 3?53 10?9
CI: Confidence interval.
FIG. 3. Maximum fall (%) in FEV1. Formoterol (&),
terbutaline ( ), placebo (&). *P50?05, ***P50?001, NS:
not significant.Discussion
In this study, formoterol 9mg gave a statistically signifi-
cantly better bronchoprotection against repeated exercise
challenge than both terbutaline 0?5mg and placebo from
15min up to 12 h after inhalation, in adult asthmatics on
regular treatment with formoterol. This supports the
findings of another study in children and adolescents,
which demonstrated that a single dose of inhaled formoter-
ol 4?5 or 9 mg gave significantly better protection against
repeated exercise challenge for up to 12 h compared with
placebo and from 4h compared with terbutaline 0?5mg
(14). The sustained bronchoprotective effect of at least 12 h
seen with formoterol contrasts with that reported for short-
acting b2-agonists. The latter usually have a protection
against EIB that lasts for a shorter time than the
bronchodilatory effect (15,16). The benefit of maintained
protection is obvious; the patient can carry out all kinds of
physical activities for up to 12 h after treatment without
needing to fear bronchoconstriction.
For both formoterol 9 mg and terbutaline 0?5mg the
bronchodilatory effect was limited (8?5% and 5?9%,
respectively), which could be explained by the selection ofnd differences between treatments
aximum % fall in FEV1
n ECT 4h after drug inhalation
P-value Estimation 95% CI P-value
— 17?6 15?0 20?2 —
— 9?53 6?94 12?1 —
— 22?2 19?5 24?8 —
50?001 12?6 8?92 16?3 50?001
50?001 4?52 0?81 8?24 0?02
0?03 8?11 4?45 11?8 50?001
aximum % fall in FEV1
ECT 12 h after drug inhalation
P-value Estimation 95% CI P-value
— 21?6 18?7 24?5 —
— 17?3 14?3 20?2 —
— 21?7 18?7 24?8 —
50?001 4?46 0?25 8?67 0?04
0?90 0?13 74?09 4?34 0?95
50?001 4?34 0?19 8?49 0?04
FORMOTEROL TURBUHALER1 IN EXERCISE 489mild asthmatics, using GCSs, who had a mean baseline
FEV1 value (at visit 2) of 89?6% (range 70?2–110?0%) of
predicted normal. Moreover, the patients’ ability to
respond to a b2-agonist was not required for inclusion into
this study. Although all patients had been using inhaled
GCSs on a regular basis for at least 1 month prior to
inclusion in the study, they had a maximum fall in
FEV115%.
The decrease in the maximum percentage fall in FEV1
after the 4-h ECT in the placebo group could be explained
by diurnal variation or by attenuation in the response after
repeated testing. However, the latter is unlikely because the
interval between ECTs in this study was 4 h and the
recovery time after an ECT is normally 2 h (17). The
bronchoprotective effect shown in this study confirms the
benefit of adding formoterol to inhaled GCS treatment, not
only as a regular treatment in patients with persistent
asthma (18) but also when needed for bronchoprotection
against EIB.
The primary objective of this study was to evaluate the
protective effect of adding formoterol 9 mg against repeated
exercise during 12 h compared with placebo and terbutaline
0?5mg, so to avoid a carry-over effect from the last dose
prior to first ECT, the evening dose scheduled to be taken
12 h prior to the exercise challenge was omitted. Consider-
ing that formoterol in fact showed protective effect vs.
placebo at 12 h justifies this procedure. The bronchopro-
tective effect of formoterol after 12 h was small and its
clinical importance may be questioned. However, it was
measured at the end of the recommended dosing interval
and the following dose of formoterol would renew the
protection. In contrast, an earlier study demonstrated
that formoterol 12 mg significantly protected against
methacholine-induced bronchoconstriction for up to 24 h
compared with placebo, perhaps suggesting that the type of
stimulus may influence the duration of protective effect
(19).
Although the patients in this study received 9mg
formoterol b.i.d. (in addition to inhaled corticosteroids)
for a mean treatment period of 16 days (range 8–44 days),
tolerance development was not investigated. Hence, to what
degree tolerance occurred, if any, remains unknown as no
ECT was performed prior to the start of regular treatment
with formoterol. Other studies have indicated that there is
an association between regular use of long-acting
b2-agonists and development of tolerance, resulting in
reduced bronchoprotective effect against exercise and
methacholine challenge but maintained bronchodilating
effects (11,12). Nevertheless, one of these studies
demonstrated that after 2 weeks of continuous dosing
with formoterol the resulting bronchoprotection was
significantly better than placebo and similar to terbu-
taline (12).
The impact of withdrawal of b2-agonist treatment for a
short time on the tolerance development has also been
investigated. In one study, it was observed that stopping
b2-agonist treatment for a short time enhances the recovery
of tolerance against systemic effects in patients using
inhaled steroids (20). However, other studies, published
by the same group, have shown that stopping treatmentwith formoterol for up to 36 h did not influence the
tolerance development to bronchoprotective effect against
methacholine (12,21).
Different bronchoconstrictor stimuli appear to have
varying effects on the ability of b2-agonists to provide and
maintain bronchoprotection. For instance, the protective
effect induced by terbutaline has shown a more rapid
decline against inhaled adenosine 5’-monophosphate
(AMP) than methacholine (22). Methacholine is a direct
stimulus whereas exercise and AMP are both indirect
bronchoconstrictors. AMP probably induces bronchocon-
striction in subjects with asthma through release of
histamine from airway mast cells, and exercise-induced
bronchoconstriction may be mediated by hypertonic mast-
cell degranulation (23). In one study, regular formoterol
24mg once daily induced a similar degree of subsensitivity
to AMP bronchial challenge as formoterol 24mg twice
daily, suggesting that even with a 24-h dosing interval,
tolerance may develop to formoterol (24). However, in a
second study, a single dose of formoterol 12mg had a
greater protective effect against AMP than against hista-
mine challenge, suggesting that formoterol may have a
mast-cell stabilizing effect in vivo in mild asthma (25).
Hence, preliminary evidence suggests that formoterol may
provide better protection against indirect than direct
stimuli. Furthermore, any tolerance development following
regular treatment plateaus after a short time to remain at a
level significantly better than seen with placebo and at least
as good as that observed with short-acting b2-agonists.
In conclusion, this study showed that a single 9mg dose of
formoterol Turbuhaler1 gave significantly better protec-
tion against EIB than either terbutaline Turbuhaler1
0?5mg or placebo for up to 12 h after inhalation, in
patients on regular treatment with formoterol Turbuhaler1
9mg b.i.d.
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